New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For HITK;AEZS;AMED;IMGN;HTWR;CRVL;SQNM;MDAS;DSCI;CCRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
10:00 EDTAMEDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Amedisys (AMED) upgraded to Outperform from Perform at Oppenheimer... American Campus (ACC) upgraded to Buy at Canaccord... Beacon Roofing (BECN) upgraded to Strong Buy from Outperform at Raymond James... Big 5 Sporting (BGFV) upgraded on potential Sports Authority closures at Stifel... CenterState Banks (CSFL) upgraded to Outperform from Market Perform at Fig Partners... Cisco (CSCO) upgraded to Neutral from Underperform at Macquarie... Dollar Tree (DLTR) upgraded to Outperform from Market Perform at Telsey Advisory... Dow Chemical (DOW) upgraded to Positive from Neutral at Susquehanna... Essex Property Trust (ESS) upgraded to Buy from Neutral at Mizuho... Globant (GLOB) upgraded to Buy from Neutral at Citi... Kinross Gold (KGC) upgraded on valuation, higher gold price at BMO Capital... L Brands (LB) upgraded to Buy from Hold at Brean Capital... Marvell (MRVL) upgraded to Buy from Sell at B. Riley... Munich Re (MURGY) upgraded to Neutral from Underperform at Credit Suisse... OM Asset Management (OMAM) upgraded to Buy from Neutral at Citi... Orbital ATK (OA) upgraded to Overweight from Sector Weight at KeyBanc... SCANA (SCG) upgraded to Buy from Neutral at Mizuho... Sensient (SXT) upgraded to Buy from Hold at Gabelli... St. Jude Medical (STJ) upgraded to Hold from Sell at Canaccord... Suffolk Bancorp (SCNB) upgraded to Outperform from Market Perform at Fig Partners... Supernus (SUPN) upgraded to Buy from Hold at Jefferies... Ultimate Software (ULTI) upgraded to Outperform from Market Perform at FBR Capital... ZAGG (ZAGG) upgraded to Outperform from Market Perform at Northland... athenahealth (ATHN) upgraded to Buy from Hold at Topeka.
06:19 EDTAMEDAmedisys upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
February 4, 2016
16:22 EDTCRVLCorVel files to sell 625K shares of common stock for holder
Subscribe for More Information
08:09 EDTIMGNImmunoGen, Merck establish collaboration for Mirvetuximab Soravtansine, Keytruda
Subscribe for More Information
February 1, 2016
12:13 EDTIMGNOn The Fly: Top stock stories at midday
Stocks on Wall Street were lower at midday, but off their worst levels of the day, as oil is once again being weighed on by worries of slower growth in China. Several M&A announcements helped fuel speculation that deal-making may be set to pick up, but the headwinds of lower oil prices and weak economic data are outweighing that potential boost and keeping stocks in the red to start the month. ECONOMIC EVENTS: In the U.S., personal income rose 0.3% in December, versus expectations for an increase of 0.2%, while spending was flat, versus expectations for an increase of 0.1%. Markit's manufacturing purchasing managers index for January dipped to 52.4 in the final January reading, down from the 52.7 flash reading and the below the 52.6 reading that was expected. The Institute for Supply Management's manufacturing index for January came in at 48.2, below the 48.4 that analysts expected. Construction spending rose 0.1% in December, which was weaker than the 0.6% increase that was forecast. In China, the statistics bureau's official manufacturing purchasing managers index fell to 49.4 in January from 49.7 in December. The private Caixin manufacturing PMI edged up to 48.4 from 48.2 in the prior reading, but both figures still remain in contraction territory. In Europe, Markit's manufacturing PMI for the euro zone dropped to 52.3 from December's 53.2, in-line with the earlier flash estimate. COMPANY NEWS: Shares of Twitter (TWTR) advanced 9% after tech reporter Jessica Lessin said private equity firm Silver Lake and investor Marc Andreessen have "considered some sort of deal" for the microblog service operator. Lessin noted in the report published on her site, The Information, that she did not know if deal talks are "active" now between Andreessen, Silver Lake and Twitter... Alere (ALR) surged 45% to $54 per share near midday after Abbott (ABT) agreed to acquire the company for $56 per share at a total expected equity value of $5.8B. In other Monday M&A news, Questar (STR) rose 22% after Dominion Resources (D) agreed to acquire it for $25 per share, or about $4.4B, and assume Questar's outstanding debt. Meanwhile, Stryker (SYK) announced a deal to acquire Sage Products for $2.775B in cash. The buyers' shares did not fare as well in the wake of the deal announcements, as Abbott slipped 0.5%, Dominion dipped 1% and Stryker fell 1%. Also lower were shares of Smith & Nephew (SNN), which slid fractionally as investors may have been concerned that Stryker's deal decreases the likelihood that it will come after S&N. Additionally, Smith & Nephew announced that its CEO Olivier Bohuon has been diagnosed with a "highly treatable" form of cancer. MAJOR MOVERS: Among the notable gainers was Lumber Liquidators (LL), which gained 8.5% after a judge accepted the company's $10M plea deal to settle timber source crime charges, according to media reports. Also higher was Chipotle (CMG), which rose 5.5% after The Wall Street Journal reported that the Centers for Disease Control and Prevention is expected to formally declare the end to its E.coli outbreak as soon as today. In addition, Sysco (SYY) and Aetna (AET) were up 7% and 2%, respectively, after reporting quarterly earnings. Among the noteworthy losers was Nokia (NOK), which fell 12% after it forecasted how much revenue it expects to gain from its IP portfolio after its patent deal with Samsung (SSNLF) and its shares were downgraded at Canaccord and BofA Merrill Lynch. Also lower was GoPro (GPRO), which was slid 5% after analysts from Piper Jaffray and Citi predicted that the company's guidance to be issued this week will disappoint investors. In addition, Roper Technologies (ROP) and ImmunoGen (IMGN) were down 6.5% and 5.7%, respectively, after reporting quarterly earnings. INDEXES: Near midday, the Dow was down 56.40, or 0.34%, to 16,409.90, the Nasdaq was down 12.25, or 0.27%, to 4,601.70, and the S&P 500 was down 6.51, or 0.34%, to 1,933.73.
January 29, 2016
17:14 EDTDSCIRA Capital reports 8% passive stake in Derma Sciences
Subscribe for More Information
06:32 EDTIMGNImmunoGen backs FY16 revenue $70M-$80M, consensus $75.14M
Subscribe for More Information
06:31 EDTIMGNImmunoGen reports Q2 EPS (38c), consensus (36c)
Subscribe for More Information
January 28, 2016
14:29 EDTIMGNNotable companies reporting before tomorrow's open
Subscribe for More Information
13:34 EDTHTWRHeartWare upgraded to Outperform from Market Perform at Wells Fargo
11:11 EDTHTWRHeartWare rallies after scrapping Valtech acquisition
The shares of HeartWare (HTWR) are surging after the company announced that would terminate its acquisition of privately held Valtech. Two research firms reacted positively to the news, with Leerink Swann saying that the company made the right decision, given its current difficulties and Raymond James upgrading HeartWare following the news. HeartWare develops and manufactures miniaturized implantable heart pumps, while Valtech has developed a method of replacing mitral valves in human hearts without the need for open heart surgery. WHAT'S NEW: HeartWare decided to terminate its acquisition of Valtech, the companies announced this morning. Pursuant to the terms of the agreement, HeartWare will make a $30M loan to Valtech in the form of a convertible promissory note. ANALYST REACTION: HeartWare's decision to abandon its acquisition of Valtech was correct in light of the problems that the company is facing with its next generation MVAD pump, Leerink analyst Danielle Antalffy wrote in a note to investors today. Noting that two weeks ago HeartWare announced that it would investigate suction issues that the device has had, the analyst says that fixing the pump could require additional investment, while it's uncertain how long it will take to solve the device's problems. However, the analyst remained upbeat on Heartware's current LVAD products, and believes that it can compete with next generation systems. She kept a $60 price target and Outperform rating on the shares. Raymond James upgraded HeartWare to Outperform from Market Perform, saying that the termination of the Valtech deal removes an overhang on the shares, while the stock's underperformance since September has made its valuation more attractive. Moreover, the stock does not appear to be giving any value to the problematic MVAD pump and the company has a 37% share of a $760M market that has only two main competitors and high barriers to entry, the firm wrote. WHAT'S NOTABLE: In early October 2015, activist investor Engaged Capital urged HeartWare to terminate the Valtech deal. Today HeartWare announced that it would, in conjunction with Engaged Capital, "jointly select" an independent party who will join Heartware's board. ANOTHER TO WATCH: HeartWare's chief rival, Thoratec, was acquired last year by St. Jude Medical (STJ). PRICE ACTION: In late morning trading, HeartWare rose 10% to $37.95. St. Jude, which reported its fourth quarter results and gave fiscal year guidance this morning, is down 1.4% to $53.56.
09:50 EDTHTWRHeartWare upgraded to Outperform from Market Perform at Raymond James
Subscribe for More Information
09:38 EDTHTWRHeartWare likely to trade 'sharply higher' on deal termination, says Leerink
Subscribe for More Information
06:14 EDTHTWRHeartWare announces cooperation agreement with Engaged Capital
Subscribe for More Information
06:13 EDTHTWRHeartWare, Valtech Cardio announce termination of proposed acquisition
Subscribe for More Information
January 27, 2016
10:31 EDTMDASPamplona Capital completes acquisition of MedAssets
Pamplona Capital Management has completed the acquisition of MedAssets. As a result of the transaction, MedAssets stock will stop trading at the close of business today. Pamplona purchased MedAssets for $31.35 per share, which represents a total enterprise value of approximately $2.7B. The transaction was overwhelmingly approved by stockholders on January 14, with 99.8% of total votes cast in favor. Separately, Pamplona has entered into an agreement with Vizient to divest MedAssets' Spend and Clinical Resource Management segment to Vizient. That transaction is expected to be completed in mid-February 2016.
January 26, 2016
18:18 EDTMDASS&P announces changes to S&P 500, S&P SmallCap 600 indices
Subscribe for More Information
17:19 EDTMDASZELTIQ to replace MedAssets in S&P 600 as of 1/29 close
Subscribe for More Information
08:32 EDTAEZSAeterna Zentaris files international patent application for Zoptrex method
Subscribe for More Information
06:33 EDTIMGNImmunoGen earns milestone payment from Bayer related to BAY 94-9343
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use